Bo Liang

Staff Fellow at FDA/CBER

Speaker

Bo Liang, Ph.D., is a CMC reviewer in the Office of Therapeutic Product (OTP), Center for Biologics Evaluation and Research (CBER). Dr. Liang is primarily responsible for reviewing oncolytic viruses and viral vector-based gene therapies. He also has experience reviewing other gene therapy products, including ex vivo genetically modified cells, plasmids, etc. Since joining CBER in 2019, he has worked on numerous pre-INDs, INDs, BLAs, and BLA supplements, participated in GMP inspections, contributed to developing regulatory guidance documents, and engaged in various outreach activities with stakeholders. Dr. Liang earned his Ph.D. degree from the University of Missouri-Columbia and completed his postdoctoral training at the National Institute of Allergy and Infectious Diseases (NIAID), NIH. (113 words)